Becker's Hospital Review

52 CMO / CARE DELIVERY How Intermountain connects COVID-19 patients to antibody treatments within 2 days of a positive test By Mackenzie Bean W hile the FDA granted emergency use authorization to Re- generon and Eli Lilly's antibody treatments in November 2020, many healthcare organizations have been slow to adopt these treatments due to a web of logistical challenges. The treatment entails a one-hour infusion followed by a one-hour monitoring period that must be performed in healthcare settings capable of managing an anaphylactic reaction in the rare instance it occurs. "at's a long time to have someone in a devoted space where they need to have nursing resources and supervision," said Brandon Webb, MD, an infectious disease physician at Salt Lake City-based Intermountain Healthcare. What's more, infusion centers typically treat patients with cancer or autoimmune diseases who have suppressed immune systems, so bringing actively contagious COVID-19 patients to these settings for antibody treatment also poses infection control hurdles. Dr. Webb spoke with Becker's about how Intermountain overcame these obstacles to roll out a successful antibody treatment program that's reached at least 1,000 patients, alongside a research effort to bet- ter understand real-world efficacy. Editor's note: Responses have been edited for length and clarity. Question: How did Intermountain ensure antibody treat- ments were going to the patients who would benefit from them the most? Dr. Brandon Webb: Once it became clear that the two antibody prod- ucts were going to be authorized by the FDA, we realized we were go- ing to be in a situation again — just like with remdesivir — where our supply was far less than our demand. At that point, we were headed into the peak of our community transmission. e number of cases was the highest ever in the pandemic. At the state level, we partici- pated with other health systems, including [Nashville, Tenn.-based] HCA Healthcare, [Dallas-based] Steward Health Care and others, and collectively decided we wanted to focus the limited capacity we did have on patients who were at the highest risk of hospitalization and most likely to benefit. Rather than doing some type of first-come, first-serve model or lottery system, we used a clinical prediction score that was adapted from a previously published risk score. We validated that score in a population of more than 22,000 Utah patients to make sure it accurately stratified patients for their hospitalization risk. Once we determined that the risk score was indeed accurate, we vot- ed to adopt it as our eligibility criteria at a state level. e reason we did not use the FDA's emergency use authorization criteria was this: We recognized very early on that the FDA's eligibility criteria would capture more than 25 percent of all positive patients. In November and December, that meant there would be hundreds and hundreds of eligible patients every single day. It was pretty obvious we didn't have enough drug nor infusion center capacity to treat all those patients. By using a more refined risk score, we were able to match the supply or the capacity to infuse to patients who were at the highest risk and stood to benefit the most. at risk-adapted strategy has actually been a very good investment at the state level. Q: How did you inform patients they were eligible for an- tibody treatments? BW: We set up a dedicated referral hotline and email inbox so that primary care physicians and other physicians across the referral area could very easily assess eligibility and then send in a referral. Many people with COVID-19 are not connected to healthcare. eir only connection is their test, and in many cases, those tests are just done at a drive-thru site. So the majority of patients with COVID-19 haven't checked into primary care. Relying only on referrals was not likely to identify the patients who were at most risk. Right now, Intermountain Laboratories are doing about 50 percent of all testing in Utah. And because of the research platform we built, every day we have a list gen- erated of everyone with a positive test. So we built the risk calculator that was adopted at the state level into that daily list. We also recruited about a dozen redeployed physicians and advanced practice providers who were furloughed or had slow practices to form what we call the "Mab squad," short for monoclonal antibodies. eir role is to field referrals through the hotline and email. And then maybe more importantly, they would go through the list of positive patients and proactively reach out to them, verify their eligibility, let them know there is a therapy they are eligible for, talk to them about the risks and benefits. For patients who were interested, these clini- cians would then make an appointment at the nearest infusion site, write the orders and coordinate with those infusion sites on any reac- tions that might occur. at prospective identification of patients has been really effective and gratifying to watch because it captures a lot of patients who wouldn't know about the treatment or would poten- tially have had long delays in accessing the treatment. We're averaging about 48 hours from the time of testing until the time of treatment — so less than a two-day span is the time for patients to get tested, find out they're positive and then get in to receive the antibody treatment. Q: How did you ensure infusion sites could safely treat both COVID-19 patients and cancer patients? BW: First we looked at our integrated health network's geographic footprint, where our population density was and where COVID-19 case density was to pinpoint where it made most sense to open in- fusion sites. We worked with these centers to develop creative ways to open infusion times starting at 1 or 2 in the aernoon and going late into the evening so they could serve the oncology patients in the morning and then have no overlap and pivot to serve COVID-19 patients in the aernoon and evening. at really helped with over- coming that barrier of infection control. With the number of can- "By using a more refined risk score, we were able to match the supply or the capacity to infuse to patients who were at the highest risk." - Dr. Brandon Webb, Intermountain Healthcare

• Cover